Back to Screener

Prestige Consumer Healthcare Inc. (PBH)

Price$45.95
Value ScoreB
Growth ScoreC
Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-35.60%
Price vs S&P 500 (4W)-18.69%
VGM Score46.36
Market Capitalization$2.25B
P/E Ratio (Annual)11.83x

All Metrics

P/CF (Annual)8.74x
Book Value / Share (Quarterly)$39.89
Revenue Growth (3Y)-1.17%
Cash Flow / Share (Quarterly)$5.21
Price vs S&P 500 (YTD)-33.89%
Gross Margin (TTM)54.71%
Net Profit Margin (TTM)17.48%
EPS (TTM)$3.91
10-Day Avg Trading Volume0.86M
EPS Excl Extra (TTM)$3.91
Revenue Growth (5Y)2.91%
EPS (Annual)$3.91
ROI (Annual)6.55%
Gross Margin (Annual)54.71%
Net Profit Margin (5Y Avg)13.31%
Cash / Share (Quarterly)$1.35
P/E Basic Excl Extra (TTM)11.83x
Revenue Growth QoQ (YoY)-5.03%
EPS Growth (5Y)3.71%
P/E Normalized (Annual)11.83x
ROA (Last FY)5.45%
Revenue Growth TTM (YoY)-4.31%
EBITD / Share (TTM)$6.78
ROE (5Y Avg)8.35%
Operating Margin (TTM)28.42%
Cash Flow / Share (Annual)$5.21
P/B Ratio1.19x
P/B Ratio (Quarterly)1.49x
Net Income / Employee (Annual)$317,200
EV / Revenue (TTM)2.94x
Net Interest Coverage (TTM)7.08x
ROA (TTM)5.49%
EPS Growth QoQ (YoY)12.90%
EV / EBITDA (TTM)9.70x
EPS Incl Extra (Annual)$3.91
Current Ratio (Annual)3.57x
Quick Ratio (Quarterly)2.12x
3-Month Avg Trading Volume0.56M
52-Week Price Return-43.74%
EV / Free Cash Flow (Annual)13.01x
P/E Incl Extra (TTM)11.83x
Revenue / Employee (TTM)$1,814,500
Tangible BV / Share (Quarterly)$-26.59
P/S Ratio (Annual)2.07x
Asset Turnover (Annual)0.31x
52-Week High$87.12
Operating Margin (5Y Avg)23.32%
EPS Excl Extra (Annual)$3.91
CapEx CAGR (5Y)-12.82%
26-Week Price Return-19.67%
Quick Ratio (Annual)2.12x
13-Week Price Return-32.30%
Total Debt / Equity (Annual)0.54x
Current Ratio (Quarterly)3.57x
Enterprise Value$3.21B
Revenue / Share Growth (5Y)3.69%
Asset Turnover (TTM)0.31x
Book Value / Share Growth (5Y)7.94%
Revenue / Employee (Annual)$1,814,500
Inventory Turnover (Annual)3.21x
Pretax Margin (Annual)23.65%
Cash / Share (Annual)$1.35
3-Month Return Std Dev39.83%
Gross Margin (5Y Avg)55.70%
Net Income / Employee (TTM)$317,200
EBITDA CAGR (5Y)1.35%
EBITDA Interim CAGR (5Y)4.64%
ROE (Last FY)10.08%
Net Interest Coverage (Annual)7.08x
EPS Basic Excl Extra (Annual)$3.91
P/FCF (TTM)9.14x
Receivables Turnover (TTM)5.64x
EV / Free Cash Flow (TTM)13.01x
Total Debt / Equity (Quarterly)0.54x
EPS Incl Extra (TTM)$3.91
Receivables Turnover (Annual)5.64x
ROI (TTM)6.62%
P/S Ratio (TTM)2.07x
Pretax Margin (5Y Avg)17.80%
Revenue / Share (Annual)$22.35
Tangible BV / Share (Annual)$-28.62
Forward P/E10.13x
Free OCF CAGR (5Y)2.92%
Price vs S&P 500 (52W)-71.94%
P/E Ratio (TTM)11.83x
EPS Growth TTM (YoY)-8.75%
Year-to-Date Return-22.95%
5-Day Price Return-0.98%
EPS Normalized (Annual)$3.91
ROA (5Y Avg)4.24%
Net Profit Margin (Annual)17.48%
Month-to-Date Return-15.61%
Cash Flow / Share (TTM)$-1.01
EBITD / Share (Annual)$6.78
EPS Growth (3Y)1.99%
Operating Margin (Annual)28.42%
LT Debt / Equity (Annual)0.53x
P/CF (TTM)8.74x
ROI (5Y Avg)5.07%
P/E Excl Extra (TTM)11.83x
LT Debt / Equity (Quarterly)0.53x
EPS Basic Excl Extra (TTM)$3.91
P/B Ratio (Annual)1.49x
Inventory Turnover (TTM)3.21x
Pretax Margin (TTM)23.65%
Book Value / Share (Annual)$39.89
Price vs S&P 500 (13W)-42.05%
Net Margin Growth (5Y)0.02%
Beta0.35x
P/FCF (Annual)9.14x
Revenue / Share (TTM)$22.82
ROE (TTM)10.29%
52-Week Low$42.62
vGradeB
gGradeC
mGradeD
vgmGradeC
Show chart for

Earnings Surprise History

Q4 261.23est. 1.40

Analyst Recommendations

Mar 2026
Apr 2026
May 2026
Jun 2026
4.20
4.20
4.20
4.00

Industry Peers — Pharmaceuticals(550)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
PBHPrestige Consumer Healthcare Inc.
BCD$45.95
LLYEli Lilly & Co.DBB$1082.20
JNJJohnson & JohnsonCCC$223.51
ABBVABBVIE INC.DCC$212.93
MRKMerck & Co., Inc.CCC$115.17
NVSNovartis AGCCC$145.68
AZNAstraZeneca PLCDBC$179.71
NVONovo-Nordisk A/SBBC$44.07
PFEPfizer Inc.BCC$25.63
ABTAbbott LaboratoriesCCD$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary SharesCCC$34.64

About

Prestige Consumer Healthcare is a leading pure-play OTC healthcare provider with a portfolio of category-dominant brands including Clear Eyes, Dramamine, Monistat, and Summer's Eve. These brands maintain strong market positions backed by healthcare professional endorsements. The company generates approximately 85% of revenue from North America, with the remainder from Australia, New Zealand, and select Asian markets.